Laidlaw Initiates Curis(CRIS.US) With Buy Rating, Announces Target Price $20
JonesTrading Maintains Curis(CRIS.US) With Buy Rating, Maintains Target Price $18
Analysts Offer Insights on Healthcare Companies: Curis (CRIS), Scholar Rock Holding (SRRK) and Travere Therapeutics (TVTX)
H.C. Wainwright Maintains Curis(CRIS.US) With Buy Rating, Maintains Target Price $26
Curis Analyst Ratings
Buy Rating Affirmed for Curis on Emavusertib's Promising Clinical Data and Market Potential
Truist Financial Maintains Curis(CRIS.US) With Buy Rating
Truist Financial Sticks to Its Buy Rating for Curis (CRIS)
Truist Financial Maintains Curis(CRIS.US) With Buy Rating
Truist Financial Reaffirms Their Buy Rating on Curis (CRIS)
Curis Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Curis, Maintains $26 Price Target
JonesTrading Maintains Curis(CRIS.US) With Buy Rating, Maintains Target Price $18
H.C. Wainwright Maintains Curis(CRIS.US) With Buy Rating, Maintains Target Price $26
Buy Rating Affirmed for Curis on Strong Financials and Promising Emavusertib Trials
Curis Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Curis (CRIS), Health Catalyst (HCAT) and Innate Pharma SA (OtherIPHYF)
Truist Financial Releases a Buy Rating on Curis (CRIS)
Curis Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Curis, Maintains $26 Price Target
No Data
No Data